Dermata Therapeutics (DRMA) and Revance Therapeutics (RVNC) said Tuesday they signed a collaboration agreement for a clinical study that will evaluate the use of Dermata's xyngari with Revance's daxxify for the treatment of primary axillary hyperhidrosis, which is a chronic condition that causes excessive armpit sweating.
The randomized 16-week phase 2a trial trial will compare xyngari with daxxify versus xyngari with placebo, tracking reductions in sweat production and other efficacy measures, the companies said.
Dermata previously demonstrated positive safety and efficacy results when pairing xyngari with a botulinum toxin in early clinical trials, they added.
Xyngari is a topical Spongilla powder that creates microchannels in the skin, supporting a needle-free method to deliver botulinum toxin, according to the companies.
Price: 3.65, Change: -0.04, Percent Change: -0.95
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.